Protecting the NHS' staff: AI medical surveillance to measure viral exposure.

我们打算开发一个自主的、基于人工智能的医疗监测系统，该系统可以真实的实时测量和模拟一线医务人员的病毒暴露。为了捕获这些数据，我们将开发一种独特适用于医院环境的新型可穿戴设备，以提供物联网风格的数据，这些数据是由可靠的、商业化的现成产品捕获的，这些产品再次以创新的方式被重新利用。在操作创新中，可以测量工作人员所面临的风险，并将此风险降至最低：核工业中成功运行的工作流程。这些信息和技术将使该国能够为下一次感染浪潮、SARS-CoV-2突变或人畜共患病做好准备，以挑战卫生服务。- -我们未来的目标是将系统开发到TRL 6，以便能够在真实的生活中部署。我们的战略由三个方面组成，即：快速开发V2.0，低成本，强大，功能齐全的可穿戴设备版本，结合从构建原型中吸取的教训。第二，在良性临床环境中快速测试此V2.0设备，以便在较长时间内对其进行操作测试。第三，开发一个最小功能版本的设备，为超低成本的可穿戴设备量身定制。在完成这些环节后，该系统将在正确的成本和证明的功效范围内成功推向市场。

We intend to develop an autonomous, AI based, medical surveillance system that measures and models the viral exposure of front line medical staff in real time. To capture this data we shall develop a novel wearable device, uniquely suited to a hospital environment, to provide IoT style data, captured by reliable, commercial off the shelf products that have been repurposed, again in a innovative way. In an operational innovation, the risk that the staff are exposed to, may then be measured and this risk minimised: a workflow successfully in operation in the nuclear industry. This information and technology will allow the country to prepare for the next infective wave, SARS-CoV-2 mutation or zoonotic disease to challenge the health service. -------------------------------------------------------------------------------- The underlying technologies are now developed and shown to work well at TRL 4, in which the individual components of the system operate together in laboratory conditions. Our future intention is to develop the system to TRL 6, at pace, so that it is capable of deployment in real life. Our strategy is composed of three strands, namely: quickly develop a V2.0, low cost, robust, fully featured, version of the wearable device, incorporating the lesson learnt from building the prototype. Secondly, quickly move to testing this V2.0 device in a benign clinical setting to test it in operation over a significant duration. Thirdly, develop a minimally featured version of the device, tailored to an ultra low cost wearable. On completion of these strands, the system will be within the correct costings and proven efficacy to be introduced to the market successfully.